Biochemist's work helps new company focus on potential hepatitis B cure

Jul 16, 2014 by Stephen Chaplin
A picture of hepatitis B particles magnifed 40,000 times showing round particles and the envelope and interior capsid within the round particles. Credit: Indiana University

An Indiana University biochemist's discovery of a class of anti-viral small molecules that target the function of a virus DNA hidden in the infected livers of hepatitis B patients may lead to a cure for this viral infection that kills more than 600,000 people annually.

Adam Zlotnick, a professor of molecular and cellular biochemistry in the IU Bloomington College of Arts and Sciences, and four colleagues—chemistry professor Richard DiMarchi and biochemistry visiting scholar William Turner, both of IU Bloomington; Indianapolis biotechnology entrepreneur Derek Small; and infectious disease researcher Dr. Uri Lopatin—formed Assembly Pharmaceuticals in 2012 to develop new anti-viral drugs based on Zlotnick's discoveries. Novel compounds based on these discoveries, known as Core Protein Allosteric Modulators, or CpAMs, are capable of altering the activities of a core B protein that is essential for the virus's continued survival.

Despite the early stage of its pipeline, the promise of Assembly's novel approach attracted the interest of Nasdaq-listed Ventrus Biosciences. Last week, Ventrus stockholders voted to merge with Assembly to form a new company, Assembly Biosciences, which is now trading on Nasdaq under the ticker "ASMB," catapulting the firm from new start-up to public company in less than two years.

Assembly's anti-viral technology is based on Zlotnick's work at IU focusing on the biophysics of virus self-assembly. Many viruses have a shell, or capsid, that is made of many copies of a virus-specific protein. The Zlotnick lab has shown how purified hepatitis B core protein can spontaneously assemble, in a matter of seconds, to form soccer-ball shaped complexes that are identical to capsids in the infectious virus. By examining the mechanism of assembly, the lab's research has led to the discovery of a number of families of small molecule CpAMs that can selectively and effectively reduce viral load and key viral antigens, considered to be the best marker of a functional cure. Reduction of those viral antigens is and will be a key clinical endpoint in new drug development, Zlotnick said.

A reconstructed image of the hepatitis B capsid as calculated from data delivered by IU's cryo-electron microscope. Credit: Indiana University

In the case of hepatitis B, CpAMS combat the virus by affecting multiple aspects of the viral lifecycle, including the function of a special viral DNA called covalently closed circular DNA, or cccDNA, that is the viral reservoir hiding in the nuclei of infected liver cells. This cccDNA serves as a template for the production of viral proteins and additional copies of the viral genome, contributing to the persistence of the infection. The cccDNA is not affected by current hepatitis B therapies, which is why only 3 to 5 percent of hepatitis B patients are cured, requiring most infected individuals to take these anti-virals for the rest of their lives.

The hepatitis B virus one of the smallest human pathogens but one of the largest public health problems in the world. As many as 360 million people have chronic hepatitis B, with about 2 million of those in the United States. Chronic infection can lead to cancer and other serious liver diseases, contributing to the estimated 600,000 deaths associated with hepatitis B annually.

One of the key tools used in Zlotnick's work has been IU Bloomington's $1.7 million transmission electron microscope. Supported by funding from the National Science Foundation and the IU College of Arts and Sciences, the microscope allows researchers like Zlotnick to study samples at cryogenic temperatures, where biological specimens are held near the temperature of liquid nitrogen (about negative 196 degrees Celcius), allowing researchers to visualize hydrated samples and determine their structures to near atomic resolution. The Zlotnick lab has used cryo-electron microscopy to examine the protein-protein interactions and the protein-RNA interactions that drive hepatitis B capsid assembly.

Explore further: Degradation of viral DNA in the cell nucleus opens new Hepatitis B treatment possibilities

add to favorites email to friend print save as pdf

Related Stories

Hepatitis C virus: How viral proteins interact in human cells

May 08, 2014

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms ...

Researchers take mathematical route to fighting viruses

Mar 24, 2014

Mathematicians at the University of York have joined forces with experimentalists at the University of Leeds to take an important step in discovering how viruses make new copies of themselves during an infection.

Scientists identify key interaction in hepatitis C virus

Dec 29, 2010

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding ...

Recommended for you

Molecules that came in handy for first life on Earth

1 hour ago

For the first time, chemists have successfully produced amino acid-like molecules that all have the same 'handedness', from simple building blocks and in a single test tube. Could this be how life started. ...

Jumping hurdles in the RNA world

Nov 21, 2014

Astrobiologists have shown that the formation of RNA from prebiotic reactions may not be as problematic as scientists once thought.

New computer model sets new precedent in drug discovery

Nov 18, 2014

A major challenge faced by the pharmaceutical industry has been how to rationally design and select protein molecules to create effective biologic drug therapies while reducing unintended side effects - a challenge that has ...

Finding new ways to make drugs

Nov 18, 2014

Chemists have developed a revolutionary new way to manufacture natural chemicals and used it to assemble a scarce anti-inflammatory drug with potential to treat cancer and malaria.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Moha2005
not rated yet Jul 23, 2014
This's great news.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.